XML 38 R67.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes - Additional Information (Detail) (USD $)
 12 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Psynova
Jun. 30, 2014
Crescendo Biosciences, Inc.
Feb. 28, 2014
Crescendo Biosciences, Inc.
Jun. 30, 2014
Utah
Jun. 30, 2014
Utah
Prior to the adoption of Statement 123(R)
Jun. 30, 2014
Foreign (various jurisdictions)
Income Taxes [Line Items]                
Amount of valuation allowance increased $ 33,202,000 $ 1,605,000   $ 29,760,000       $ 3,442,000
Excess tax benefits realized 7,122,000 7,888,000            
Excess tax benefits attributable to deferred tax asset 76,986,000 8,336,000     70,048,000 92,557,000 3,008,000  
Remaining excess tax benefits not included in deferred tax assets           137,343,000    
Valuation allowance to offset foreign and miscellaneous state net operating loss carry-forwards 3,786,000              
Taxable loss of disposition of asset     15,200,000          
Cumulative effect $ 0              
Income tax returns examination The Company's New York State income tax returns for the years ended June 30, 2011, 2012 and 2013 were under examination by the New York State Department of Taxation and Finance.